Uncovering Potential: Penny Stocks To Watch In September 2026

The United States market has shown positive momentum, rising 2.5% over the last week and 14% over the past year, with earnings projected to grow by 18% annually. In this context, identifying stocks that combine affordability with growth potential becomes crucial for investors seeking opportunities in smaller or newer companies. Penny stocks, though an older term, continue to offer intriguing possibilities when backed by strong financial health; let's explore several such options that stand out for their financial strength and long-term promise.

Let's dive into some prime choices out of the screener.

Ardelyx (ARDX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to address unmet medical needs in the United States and internationally, with a market cap of approximately $872.16 million.

Operations: The company generates $450.89 million from the development and commercialization of biopharmaceutical products.

Market Cap: $872.16M

Ardelyx, Inc., a biopharmaceutical company, is navigating challenges typical of penny stocks. Despite generating US$450.89 million in revenue from its products, the company remains unprofitable with a negative return on equity of -37.38%. Recent legal issues have surfaced due to allegations of misleading statements about product performance and market access hurdles, leading to a significant stock price drop after revising revenue guidance for IBSRELA and withdrawing long-term guidance for XPHOZAH. While Ardelyx's short-term assets exceed liabilities and it trades below estimated fair value, increasing debt levels pose potential risks amidst management changes and ongoing litigation concerns.

• Dive into the specifics of Ardelyx here with our thorough balance sheet health report.
• Assess Ardelyx's future earnings estimates with our detailed growth reports.

MediciNova (MNOV)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: MediciNova, Inc. is a biopharmaceutical company dedicated to developing novel and small molecule therapeutics for serious diseases with unmet medical needs in the United States, with a market cap of approximately $162.43 million.

Operations: The company's revenue is primarily derived from the acquisition and development of small molecule therapeutics, totaling $0.92 million.

Market Cap: $162.43M

MediciNova, a pre-revenue biopharmaceutical company with a market cap of US$162.43 million, is currently focused on developing MN-166 (ibudilast) for neurodegenerative diseases like ALS. The company has no debt and its short-term assets of US$25.9 million comfortably cover liabilities, providing a sufficient cash runway for over two years. Despite unprofitability and high stock volatility, MediciNova has reduced its net loss from US$3.28 million to US$2.31 million year-over-year in Q2 2026 while increasing sales modestly to US$0.46 million. Recent conference presentations highlight ongoing clinical trials and strategic engagements within the biotech community.

• Get an in-depth perspective on MediciNova's performance by reading our balance sheet health report here.
• Gain insights into MediciNova's future direction by reviewing our growth report.

Grab Holdings (GRAB)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Grab Holdings Limited operates the Grab superapp, providing a range of services including transportation, food delivery, and digital payments across Southeast Asian countries such as Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam; it has a market cap of approximately $12.89 billion.

Operations: The company generates revenue through its main segments: Mobility ($1.31 billion), Deliveries ($1.99 billion), and Financial Services ($430 million).

Market Cap: $12.89B

Grab Holdings has demonstrated substantial earnings growth, with a 438.7% increase over the past year, surpassing both its historical average and industry benchmarks. The company's financial health is robust, with short-term assets of US$8.4 billion exceeding liabilities and cash reserves outpacing total debt. Recent strategic moves include raising its earnings guidance for 2026 to US$4.10–US$4.15 billion and engaging in acquisition talks with Atome Financial to enhance business scale. Additionally, Grab's share repurchase program aims to buy back up to US$750 million in shares, reflecting confidence in its financial position despite low return on equity at 7.3%.

• Click here and access our complete financial health analysis report to understand the dynamics of Grab Holdings.
• Learn about Grab Holdings' future growth trajectory here.

Where To Now?

• Take a closer look at our US Penny Stocks list of 318 companies by clicking here.
• Contemplating Other Strategies? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com